ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
Public ClinicalTrials.gov record NCT01100151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of the Effects of RDC-1036 Administered to Subjects With Opioid-induced Constipation During Treatment With Opioids for Chronic Pain
Study identification
- NCT ID
- NCT01100151
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alkermes, Inc.
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- RDC-1036 (ALKS 37) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Nov 30, 2010
- Completion
- Nov 30, 2010
- Last update posted
- Aug 22, 2011
2010
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Sheffield | Alabama | 35660 | — |
| Alkermes Investigational Site | Anaheim | California | 92801 | — |
| Alkermes Investigational Site | Pasadena | California | 91105 | — |
| Alkermes Investigational Site | Walnut Creek | California | 94598 | — |
| Alkermes Investigational Site | DeLand | Florida | 32734 | — |
| Alkermes Investigative Site | New Smyrna Beach | Florida | 32168 | — |
| Alkermes Investigational Site | Boise | Idaho | 83704 | — |
| Alkermes Investigational Site | New Orleans | Louisiana | 70114 | — |
| Alkermes Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Alkermes Investigational Site | Dayton | Ohio | 45432 | — |
| Alkermes Investigational Site | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01100151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01100151 live on ClinicalTrials.gov.